mg 1

MG 1 is a potent alpha-1 adrenergic receptor antagonist.

DSPE-PEG3400-MG1 is a PEG compound composed of DSPE and the MG1 peptide. The MG1 peptide serves as a microglial M1 cell-targeting peptide. It can conjugate with nanoparticles to cross the blood-brain barrier, accurately target M1 microglial cells, and achieve controlled drug release and specific accumulation through an intelligent molecular switch. DSPE-PEG3400-MG1 is suitable for drug delivery.

DSPE-PEG5000-MG1 is a PEG compound consisting of DSPE and the MG1 peptide. The MG1 peptide targets M1 microglia cells, allowing it to conjugate with nanoparticles to cross the blood-brain barrier. This enables precise recognition of M1 microglia cells and facilitates controlled drug release and specific accumulation through an intelligent molecular switch. DSPE-PEG5000-MG1 is useful for drug delivery.

DSPE-PEG2000-MG1 is a PEG compound composed of DSPE and the MG1 peptide. The MG1 peptide is an M1 microglia-targeting peptide that can couple with nanoparticles to traverse the blood-brain barrier, precisely recognize M1 microglia, and enable controlled drug release and specific accumulation via a smart molecular switch. DSPE-PEG2000-MG1 is utilized for drug delivery.

DSPE-PEG1000-MG1 is a PEG compound composed of DSPE and the MG1 peptide. The MG1 peptide is a microglia M1-targeting peptide. It can conjugate with nanoparticles, facilitating passage through the blood-brain barrier to accurately identify M1 microglia, and enables controlled release and specific accumulation of drugs via a smart molecular switch. DSPE-PEG1000-MG1 is applicable in drug delivery.

MG1 peptide is a targeting peptide for M1 microglial cells. It can be conjugated with nanoparticles to traverse the blood-brain barrier, accurately identify M1 microglial cells, and enable controlled drug release and specific accumulation through an intelligent molecular switch. MG1 peptide is applicable in drug delivery research for ischemic stroke.

Anti-mouse ICOSL/CD275 antibody, targeting ICOSL/CD275.

Concanamycin A (Folimycin), a polycyclic lactone antibiotic, is a selective inhibitor of vacuolar H+-ATPase (V-ATPase) and lysosomal acidification, and can be used to study inflammation.Concanamycin A enhances the immune clearance of infected progenitor cells by cytotoxic T lymphocytes, and inhibits Nef et al. from different branches of HIV and simian immunodeficiency virus. Concanamycin A enhances immune clearance of cytotoxic T lymphocytes from infected progenitor cells, inhibits the Nef allele from different branches of HIV and simian immunodeficiency virus, and can be used to study HIV infection.

MG-H1 is a ligand for the receptor for advanced glycation end-products (RAGE), with a Kd value of 4.12 nM. It is capable of binding to human umbilical vein endothelial cells. MG-H1 is applicable in diabetes research.

Geranylgeranyl Pyrophosphate triammonium (GGPP triammonium) is a metabolite involved in protein geranylgeranylation, modulating endothelial cell proliferation and apoptosis during mouse embryonic angiogenesis. GGPP triammonium amplifies T(reg) differentiation by increasing IL-2 expression, improving DSS-induced colitis, useful in cancer research.

1-Stearoyl-2-docosahexaenoyl-sn-glycero-3-PC is a phospholipid in biological membranes containing stearic acid and docosahexaenoic acid at the sn-1 and sn-2 positions, respectively. It has been used to study the organization and dynamics of lipid membranes. In the superoxide dismutase 1 mutant transgenic mouse model of amyotrophic lateral sclerosis (ALS) 1-Stearoyl-2-docosahexaenoyl-sn-glycero-3-PC levels decrease in the anterior horn of L5 in late stages of the disease.1-Stearoyl-2-docosahexaenoyl-sn-glycero-3-PC can be used to study biological membranes.

1-Stearoyl-2-eicosapentaenoyl-sn-glycero-3-PC is a phospholipid comprising stearic acid and eicosapentaenoic acid at the sn-1 and sn-2 positions, respectively, identified in human red blood cells (RBCs).

MG 149 (Tip60 HAT inhibitor) is a selective and potent Tip60 inhibitor with IC50 of 74 uM, similar potentcy for MOF(IC50= 47 uM).

AMG 108 (MEDI 8968) is a fully human monoclonal antibody targeting IL-1R1, used in rheumatoid arthritis research.

AMG 118 Immobilized cephalosporin C acylase is an enzyme in immobilized form used primarily in industrial catalysis for the production of the vital pharmaceutical intermediate, 7-aminocephalosporanic acid (7-ACA). The CPC acylase it contains is a highly specialized β-lactam acylase or peptidase capable of cleaving the amide bond within β-lactams.

Evolocumab is an inhibitor of the humanized monoclonal antibody PCSK9. It binds to circulating PCSK9 protein, resulting in inhibition of PCSK9 binding to LDLR. It can be used in studies of hypercholesterolemia and atherosclerotic cardiovascular disease.

MG-132 (Z-Leu-Leu-Leu-al) is a 26S proteasome inhibitor (IC50=100 nM) that is cell-permeable and reversible. MG-132 acts as an autophagy activator and also induces apoptosis.

Tezepelumab (AMG 157) is a humanized monoclonal antibody (IgG2λ) targeting TSLP that prevents TSLP from interacting with its heterodimer receptor. Tezepelumab can be used to study advanced asthma disease.

AMG-1694, a potent disruptor of the glucokinase–glucokinase regulatory protein (GK-GKRP) complex, operates by promoting the dissociation of this complex, thereby indirectly enhancing GK enzymatic activity with an IC50 of 7 nM. It effectively normalizes blood glucose levels in various rodent diabetes models [1] and lowers blood glucose specifically in diabetic animals without affecting normoglycemic ones. Additionally, AMG-1694 reverses the GKRP-induced inhibition of GK activity and facilitates GK translocation.

ARRY-403 is a novel glucokinase activator that reduces fasting and postprandial blood glucose in patients with type 2 diabetes.

hSMG-1 inhibitor 11e is an effective and selective inhibitor of hSMG-1 (IC50 <0.05 nM) and can be used in studies about cancer treatment.

WYE-125132 (WYE-132 (WYE-125132)) is a highly potent, ATP-competitive mTOR inhibitor with IC50 of 0.19 nM; highly selective for mTOR versus PI3Ks or PI3K-related kinases hSMG1 and ATR.

hSMG-1 inhibitor 11j is a pyrimidine derivative. hSMG-1 inhibitor 11j is a potent and selective inhibitor of hSMG-1, IC50 = 0.11 nM. hSMG-1 inhibitor 11j exhibits >455-fold selectivity for hSMG-1 over mTOR (IC50=50 nM), PI3Kα/γ (IC50=92/60 nM) and CDK1/CDK2 (IC50=32/7.1 μM). hSMG-1 inhibitor 11j can be used for the research of cancer.

KMG-104 is a selective Mg2+ fluorescent probe for dynamic observation of Mg2+ in the cytoplasm of living cells.